SPIE Photonics West Digital Forum Showcases Best of Optics, Photonics, Quantum, Biomedical Technologies in Applications and Research
SPIE, the international society for optics and photonics, welcomed an engaged global audience to its SPIE Photonics West Digital Forum 6-11 March with 8,000 registered attendees. Across the highly regarded BiOS, LASE, and OPTO symposia, as well as the new industry-focused Quantum West conference, SPIE Photonics West showcased more than 20 plenary speakers, including Ursula Keller, Gérard Mourou, Susumu Noda, Satoshi Kako, Kohji Mitani, Sheila Nirenberg, Laura Fabris, and Yeka Aponte. More than 100 live events – including panel sessions, technical discussions, and networking events complemented the 3,200 on-demand presentations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005651/en/
SPIE Photonics West Digital Forum showcases best of optics, photonics, quantum, biomedical technologies in applications and research (Photo: Business Wire)
In addition, two Digital Marketplaces – one for Photonics West, one for BiOS – together showcased more than 400 exhibitors and over 100 product demonstrations of the latest innovations in optics and photonics.
The largest photonics virtual event of 2021, SPIE Photonics West spotlighted and recognized the best optics and photonics technologies, trends, and entrepreneurial innovations, offering many opportunities for attendees, presenters, scientists, and engineers to engage and discuss their latest research and work. From COVID-focused diagnostics advancements and neuro-technologies to lasers in manufacturing and data center communications, SPIE Photonics West offered a dynamic week of information sharing, learning, and conversation.
Quantum West, a new conference on quantum technology held in partnership with the QED-C, featured industry leaders such as Celia Merzbacher, Peter Knight, Andrew Lord, Wilhelm Kaenders, and Kaitlin Moore exploring the role of photonics in quantum technology’s growth from R&D into engineering products for commercial applications.
"I have worked with SPIE over many years, as both an exhibitor and conference chair, and am very happy to help build Quantum West together with them,” said Quantum West Co-Chair Tim Day who serves as DRS Daylight Solutions GM and senior VP, as well as Member of the Board of ColdQuanta. “SPIE did a great job under challenging circumstances and is always a wonderful partner in terms of bringing the community together and helping to advance photonics technology. We, along with many others in the photonics community, are looking forward to an in-person meeting next January in San Francisco.”
Other industry-focused events featured live sessions with thought leaders discussing today’s hottest application areas, including industrial lasers, sensing and imaging, and autonomous vehicles.
“I come to Photonics West every year with my students,” said Jennifer Barton, who is co-chair for BiOS as well as the director of the University of Arizona’s BIO5 Institute and the university’s Thomas R. Brown Distinguished Professor of Biomedical Engineering. “This year, three of them presented virtually, along with myself. I was very impressed with the high quality of live and prerecorded presentations, the flawless execution of events, and the surprisingly effective opportunities for networking and fun – go Trivia Night! Of course, I am looking forward to seeing everyone in person next year, but I loved how engaging and informative this conference week was.”
“Photonics West is the largest biomedical, laser, and optoelectronic event in our field, even when we cannot travel,” noted SPIE Senior Director of Technical Programs Marilyn Gorsuch. “Given the virtual circumstances, our volunteer conference chairs rolled up their sleeves and produced an amazing offering to present and discuss the latest technical advancements. But nothing can replace the in-person experience and the excitement of gathering together at Photonics West in San Francisco. We are very much looking forward to hosting Photonics West in San Francisco next January.”
All the Photonics West content will be available on the SPIE Digital Library from 20 March.
Photonics West 2022 will take place 22-27 January at the Moscone Center in San Francisco. The Call for Papers will be announced and open in the next few weeks.
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alira Health Strengthens Its Growth Strategy With a $35M Funding, Led by Creadev12.4.2021 16:00:00 EEST | Press release
Alira Health (www.alirahealth.com), a leading international advisory firm dedicated to advancing healthcare and life sciences, announced it has closed a $35M equity financing led by Creadev, an evergreen investment company backed by the Mulliez family. This new partnership will help accelerate the firm’s growth strategy, focused on merging pharmaceutical, medical and digital technologies development with medical care through a patient-centric approach. “I would like to thank our team of investors for joining our mission to enable healthcare transformation. Their investment positions us to change the way life sciences advisory services are delivered,” said Gabriele Brambilla, Chief Executive Officer and Co-Founder of Alira Health. “We are building a powerful continuum of services that spans the product and solutions development life cycle, supported by the recent additions of our patient engagement, real-world evidence and advanced analytics practices. This financing allows us to advanc
KD Pharma Acquires Phytoextract and CBD Manufacturing Assets12.4.2021 15:45:00 EEST | Press release
The KD Pharma Group has acquired the manufacturing assets of a Swiss-based cannabinoid manufacturer. The assets give KD Pharma access to technology for producing Active Pharmaceutical Ingredients (APIs) based on phytocannabinoids and other plant extracts. The technology further expands KD’s lipid technology portfolio and can be used in combination with KD’s other fractionation and separation technologies. “KD Pharma is a leader in lipid technology focused primarily on omega-3s, but our technology suite has applications in other lipid sources like cannabinoids,” said Oscar Groet, CEO of the KD Pharma Group. “We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts,” Groet continued, “and these assets give KD Pharma additional pathways to develop new products for this emerging market.” The KD Pharma Group has also licensed a novel extraction method from Herbolea Biotech S.r.l. and expects to have a complete, licensed cGMP manufacturing
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis12.4.2021 15:00:00 EEST | Press release
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Vivet’s two proprietary AAV gene therapy programs for progressive familial intrahepatic cholestasis (PFIC), subtypes 3 and 2. The two programs, VTX-803 and VTX-802, are currently being evaluated in preclinical studies by Vivet, a privately-held gene therapy biotechnology company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005354/en/ Under the terms of the agreement, Vivet will continue to advance the preclinical studies for VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively. Mirum has the exclusive option to license the programs after which Mirum would lead the clinical development and any future commercialization of the programs. Until that time, Mirum will provide funding to support the continued research and development costs
Globality and BT Sourced Announce New Partnership to Unleash the Power of Procurement12.4.2021 15:00:00 EEST | Press release
Through a new partnership with Globality and BT’s new procurement company, BT Sourced, BT launched Globality’s AI-powered Smart Sourcing® Platform to transform how BT employees source and procure services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005173/en/ “BT’s changing and so is procurement. Digitization is the driving force for long-term growth and value to the BT customer and operating model,” said Cyril Pourrat, Chief Procurement Officer, BT. “Partnering with Globality will help us to embrace digital technology and simplify our processes.” “Having immediate access to our current suppliers and Globality’s diverse global network will bring agility and new value to our teams,” added Pourrat. BT now uses Globality’s AI advisor, Glo™, to quickly and easily source the best suppliers for consulting, marketing, IT, HR, legal and other service categories. “BT is revolutionizing the way it sources services in order t
FLIR Wins DARPA Contract Worth Up to $20.5M to Develop Revolutionary New Protective Fabrics for Chem-Bio Defense12.4.2021 15:00:00 EEST | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) announced it has won a contract with the Defense Advanced Research Projects Agency (DARPA) to rapidly develop novel fabrics with embedded catalysts and chemistries that can fight and reduce chemical and biological threats upon contact. The revolutionary fabrics will be incorporated into protective suits and other equipment such as boots, gloves, and eye protection that can be worn by troops on the battlefield, medical experts, healthcare workers, and more. FLIR received $11.2 million in initial funding for the potential five-year effort worth up to $20.5 million, including options. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005140/en/ The Personalized Protective Biosystems (PPB) program will create fabrics with built-in ability to fight chemical and biological agents, from VX to chlorine gas to Ebola virus. The revolutionary fabrics being developed by FLIR Systems will be incorpora
Riffyn Launches Riffyn Nexus v4.2 to Strengthen Bioprocess Data Integrity With Automated Data Validation12.4.2021 14:50:00 EEST | Press release
Riffyn's pioneering cloud-based process data system for Intelligent Process Development has been upgraded with more powerful capabilities. The new features in Riffyn Nexus v4.2 enable customers to validate data real-time at a large scale with the ability to trace the root cause of an anomaly. Data integrity in process development is critical to rapid, high-quality drug and biotech product development. Inadequate data can mislead decisions and cost tens of million dollars in lost time, resources, and investment by sending an entire product development program down the wrong path. "Riffyn Nexus now gives the complete package of capabilities needed for process developers to ensure data integrity in their decision-making, while preserving their agility to innovate," said Riffyn CEO Timothy Gardner. "The new features in Riffyn Nexus automatically check all the collected data on each experiment in real-time — 3,300 samples, parameters, or measurements checked per second." Riffyn Nexus has al
Ameriprise Financial to Acquire BMO’s EMEA Asset Management Business12.4.2021 14:00:00 EEST | Press release
Ameriprise Financial, Inc. (NYSE: AMP) today announced that it has signed a definitive agreement with BMO Financial Group (BMO) to acquire its EMEA asset management business for £615 million, or approximately $845 million. The all-cash transaction adds $124 billion of AUM in Europe and is currently expected to close in the fourth quarter of 2021, subject to regulatory approvals in the relevant jurisdictions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005470/en/ The acquisition will further accelerate Ameriprise’s core strategy of growing its fee-based businesses and increase the overall contribution of Wealth Management and Asset Management within its diversified business. Together with BMO’s EMEA asset management business, Ameriprise will have more than $1.2 trillion of assets under management and administration. The acquisition complements Columbia Threadneedle Investments’ core business and global growth strateg
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom